- Home
- ASA vs PHAT Comparison
ASA vs PHAT Comparison
Compare ASA & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASA
- PHAT
- Stock Information
- Founded
- ASA 1958
- PHAT 2018
- Country
- ASA United States
- PHAT United States
- Employees
- ASA N/A
- PHAT N/A
- Industry
- ASA Precious Metals
- PHAT Biotechnology: Pharmaceutical Preparations
- Sector
- ASA Industrials
- PHAT Health Care
- Exchange
- ASA Nasdaq
- PHAT Nasdaq
- Market Cap
- ASA 697.1M
- PHAT 769.0M
- IPO Year
- ASA N/A
- PHAT 2019
- Fundamental
- Price
- ASA $52.95
- PHAT $13.31
- Analyst Decision
- ASA
- PHAT Strong Buy
- Analyst Count
- ASA 0
- PHAT 5
- Target Price
- ASA N/A
- PHAT $16.40
- AVG Volume (30 Days)
- ASA 154.4K
- PHAT 1.4M
- Earning Date
- ASA 10-28-2025
- PHAT 11-06-2025
- Dividend Yield
- ASA 0.12%
- PHAT N/A
- EPS Growth
- ASA 335.96
- PHAT N/A
- EPS
- ASA 19.90
- PHAT N/A
- Revenue
- ASA $3,982,215.00
- PHAT $114,039,000.00
- Revenue This Year
- ASA N/A
- PHAT $213.11
- Revenue Next Year
- ASA N/A
- PHAT $91.84
- P/E Ratio
- ASA $2.62
- PHAT N/A
- Revenue Growth
- ASA 99.75
- PHAT 1049.82
- 52 Week Low
- ASA $19.37
- PHAT $2.21
- 52 Week High
- ASA $53.76
- PHAT $19.50
- Technical
- Relative Strength Index (RSI)
- ASA 81.83
- PHAT 63.30
- Support Level
- ASA $46.18
- PHAT $11.49
- Resistance Level
- ASA $49.14
- PHAT $13.85
- Average True Range (ATR)
- ASA 1.81
- PHAT 1.03
- MACD
- ASA 0.40
- PHAT 0.16
- Stochastic Oscillator
- ASA 94.02
- PHAT 84.65
About ASA ASA Gold and Precious Metals Limited
ASA Gold And Precious Metals Ltd is a closed-end, non-diversified investment company. Its objective is to provide long-term capital appreciation through investing in companies engaged in the exploration for, development of projects, or mining of precious metals and minerals.
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.